BRIEF-Veru Receives FDA Agreement To Advance Veru-111 Into Phase 3 Study In Hospitalized Covid-19 Patients At High Risk For Acu

路透社 · Mar 1, 2021 22:57

March 1 (Reuters) - Veru Inc :
   * VERU RECEIVES FDA AGREEMENT TO ADVANCE VERU-111 INTO PHASE 3 STUDY IN HOSPITALIZED COVID-19 PATIENTS AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
   * VERU INC - VERU COMPLETES EXPEDITED END OF PHASE 2 TRIAL MEETING WITH FDA
   * VERU INC - PHASE 3 CLINICAL STUDY EXPECTED TO BEGIN IN APRIL 2021 WITH CLINICAL RESULTS EXPECTED IN CALENDAR Q4 2021
   * VERU INC - FDA AGREES TO ADVANCE VERU-111 INTO PHASE 3 CLINICAL STUDY IN HOSPITALIZED HIGH RISK COVID-19 PATIENTS TO CONFIRM POTENTIAL BENEFIT & RISK
   * VERU -FDA AGREES CLINICAL FINDINGS SUGGEST CLINICALLY MEANINGFUL BENEFIT FOR USE OF VERU-111 IN HOSPITALIZED COVID-19 PATIENTS AT HIGH RISK FOR ARDS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

BRIEF-Veru Receives FDA Agreement To Advance Veru-111 Into Phase 3 Study In Hospitalized Covid-19 Patients At High Risk For Acu

Risk Disclaimer